Catherine Pinkston, DO
Family Medicine · Reno, NVNPI 1962897611
Payments from drug & device makers
Across 210 payments — averaging $18.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$533
- Amgen$342
- Pfizer$259
- Novo Nordisk$167
- Lilly USA, LLC$145
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,873100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 61 | $1,103 |
| AstraZeneca | 31 | $533 |
| Amgen(2 entities) | 18 | $342 |
| Pfizer | 13 | $259 |
| Novo Nordisk | 9 | $167 |
| Lilly USA, LLC | 8 | $145 |
| Idorsia Pharmaceuticals US Inc | 9 | $144 |
| Vertex | 5 | $133 |
| GSK | 7 | $121 |
| Merck | 7 | $119 |
| Bayer | 5 | $110 |
| Boehringer Ingelheim | 5 | $93 |
| Exact Sciences | 5 | $91 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $67 |
| Abbott | 3 | $53 |
| Kowa Pharmaceuticals America, Inc. | 2 | $46 |
| Astellas Pharma US Inc | 2 | $45 |
| Sanofi-aventis U.S. LLC | 3 | $41 |
| Johnson & Johnson | 2 | $40 |
| Dexcom, Inc. | 1 | $35 |
| Corcept Therapeutics | 2 | $34 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $31 |
| Kaleo, Inc. | 1 | $29 |
| Esperion Therapeutics, Inc. | 2 | $28 |
| Medtronic | 1 | $22 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $22 |
| Lucid Diagnostics Inc. | 1 | $19 |
How this compares
$3,873 in reported general payments places this provider in the 85th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 81 | $103,366 |
| OzempicSemaglutide | 50 | $57,080 |
| TrulicityDulaglutide | 44 | $56,791 |
| JardianceEmpagliflozin | 36 | $52,339 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $39,901 |
| JanuviaSitagliptin Phosphate | 23 | $22,777 |
| Repatha SyringeEvolocumab | 25 | $17,088 |
| QuliptaAtogepant | 12 | $12,443 |
| EliquisApixaban | 16 | $11,496 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $8,757 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 36 | $7,668 |
| Atorvastatin Calcium | 393 | $5,220 |
| Wixela InhubFluticasone Propion/Salmeterol | 14 | $4,779 |
| Gabapentin | 119 | $3,643 |
| Icosapent Ethyl | 16 | $3,584 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $145 | $160,157125 claims |
| Novo NordiskOzempic | $167 | $57,08050 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $121 | $56,326106 claims |
| Boehringer IngelheimJardiance | $93 | $52,33936 claims |
| MerckJanuvia | $119 | $22,77723 claims |
| AbbVieQulipta, Synthroid | $1,103 | $15,03840 claims |
| PfizerEliquis | $259 | $11,49616 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 902 family medicine providers in Nevada.
Other family medicine in Reno
- Susan ParkReno$1.1M
- Bayo Curry-WinchellReno$74K
- Catherine McCarthyReno$68K
- Francisco DofelizReno$30K
- Michael ObrienReno$18K
- James McLennanReno$16K
- Jeremy BearfieldReno$15K
- Ricardo GonzalezReno$11K
- Jennifer HornbackReno$11K
- Ambika UppuReno$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.